ClinicalTrials.gg
CompletedNCT04572841phaethuSAUpdated Oct 9, 2025Results posted

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

A Phase 2 interventional study of SAR441344 and Placebo in Sjögren's Syndrome and Sjogren's Syndrome, sponsored by Sanofi. Completed at 36 sites in 12 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Sjogren's Syndrome with a site in France — 18 open to participants now, 25 under way, 7 of them phase 3. Sjogren's Syndrome · France.

Enrollment
28th of 40
84 · median 169
Started
2020
with 6 others
Phase 2
14 of 58
2 open now
Registered
24th of 58
by date

Among the 58 studies in Sjogren's Syndrome with a site in France, this one is the 28th largest by enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2020, is one of 14 in phase 2, and was the 24th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

18 of the 58 studies in Sjogren's Syndrome with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Sjogren's Syndrome with a site in France, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI)

Secondary Objectives:

  • To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS
  • To evaluate the therapeutic efficacy on fatigue of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS
  • To evaluate the pharmacokinetic (PK) exposure of one dose level of SAR441344 over 12 weeks in adult patients with pSjS
  • To evaluate the safety and tolerability of one dose level of SAR441344 versus placebo in adult patients with pSjS as determined by adverse events (AEs)
  • To evaluate the local tolerability of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS
  • To evaluate the safety and tolerability of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS determined by electrocardiogram, vital signs, and laboratory evaluations
  • To measure the immunogenicity of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS

This is a multicenter, randomized, double blind, placebo controlled, parallel group proof of concept Phase 2 study to evaluate the therapeutic efficacy of SAR441344 in adult patients with primary Sjögren's syndrome (pSjS), as well as safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).

  • Study visit frequency: every 2 weeks in the treatment period and every 4 weeks in the follow-up period.
  • The total duration of the study will be 24 weeks (28 weeks including maximum screening duration) for each participant, including a 12-week treatment period and a 12-week follow-up period.
03

Conditions studied

  • Sjögren's Syndrome
  • Sjogren's Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 80 years of age inclusive, at the time of signing the .
  • Diagnosis of pSjS according to the American College of Rheumatology/EULAR 2016 criteria at Screening.
  • Disease duration since first diagnosis of pSjS ≤15 years based on medical history.
  • Participants with moderate to severe disease activity set with ESSDAI total score ≥5, based on the following domains at Screening: glandular, articular, muscular, hematological, biological, and constitutional, lymphadenopathy.
  • Seropositive for anti-Ro/SSA antibodies.
  • IgG > lower limit of normal () at Screening.
  • Stimulated salivary flow rate of ≥0.1 mL/min at Screening or Baseline.
  • Body weight within 45 to 120 kg (inclusive) and within the range of 18.0 to 35.0 kg/m2 (inclusive) at Screening.
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Any disease (except pSjS and Hashimoto thyroiditis) with or without secondary SjS.
  • History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphospholipid syndrome and any participants requiring antithrombotic treatment.
  • Active life threatening or organ threatening complications of pSjS disease at the time of Screening based on treating physician evaluation including but not restricted to:

    • Vasculitis with renal, digestive, cardiac, pulmonary, or CNS involvement characterized as severe,
    • Active central nervous system (CNS) or peripheral nervous system (PNS) involvement requiring high dose ,
    • Severe renal involvement defined by objective measures,
    • Lymphoma.
  • Cardiac heart failure Stage III or IV according to the .
  • Severe pulmonary impairment documented by an abnormal pulmonary function test.
  • Serious systemic viral, bacterial or fungal infection (eg, pneumonia, pyelonephritis), infection requiring hospitalization or IV antibiotics or significant chronic viral (including history of recurrent or active herpes zoster), bacterial, or fungal infection (eg, osteomyelitis) 30 days before and during Screening.
  • Participants with a history of invasive opportunistic infections, such as, but not limited to histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, and aspergillosis, regardless of resolution.
  • Evidence of active or latent tuberculosis (TB) as documented by medical history (eg, chest X rays) and examination, and TB testing: A positive or 2 indeterminate QuantiFERON® TB Gold tests at Screening (regardless of prior treatment status).
  • Evidence of any , severe or unstable, acute or chronically progressive, uncontrolled infection or medical condition (eg, cerebral, cardiac, pulmonary, renal, hepatic, gastrointestinal, neurologic, or any known immune deficiency) or previous, active or pending surgical disorder, or any condition that may affect participant safety in the judgment of the Investigator (including vaccinations which are not updated based on local regulation).
  • History or presence of diseases which exclude diagnosis of SjS as per the American College of Rheumatology/EULAR 2016 criteria including, but not limited to, sarcoidosis, amyloidosis, , IgG4 related disease, and history of head and neck radiation treatment.
  • History of systemic reaction or significant allergies, other than localized injection site reaction, to any humanized monoclonal antibody.
  • Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
  • Any prior history of or active malignancy, including lymphoproliferative diseases and lymphoma (except successfully treated carcinoma in situ of the cervix, nonmetastatic squamous cell or basal cell carcinoma of the skin) within 5 years prior to Baseline.
  • Unstable dose of nonsteroidal anti inflammatory drugs (NSAIDs) and/or unstable use of topical and/or pharmacological stimulant treatment for salivary and lacrimal glands 4 weeks before Screening.
  • High dose steroids, or a change in steroid dose within 4 weeks prior to Day 1/Randomization or expected changes during the course of the study.
  • High dose of hydroxychloroquine or chloroquine, or methotrexate or change in hydroxychloroquine, chloroquine or methotrexate dose within 12 weeks prior to Day 1/Randomization or expected changes during the course of the study.
  • Participants treated with the following medications/procedures prior to Screening:

    • Previous treatment with azathioprine and other thiopurines, mycophenolate mofetil, sulfasalazine, or cyclosporine A within 3 months.
    • Previous treatment with cyclophosphamide, leflunomide, or belimumab within 6 months.
    • Previous treatment with rituximab within 12 months.
    • Previous bone marrow transplantation, total lymphoid irradiation or ablative ultra high dose cyclophosphamide or IV Ig.
    • Previous treatment with any other biologic drug within 5 times the half life of the drug.
  • Received administration of any live (attenuated) vaccine within 3 months prior to Day 1/Randomization (eg, varicella zoster vaccine, oral polio, rabies).
  • Clinically significant abnormal or vital signs at Screening.
  • Abnormal laboratory test(s) at Screening.
  • Positive (HIV) serology (anti HIV1 and anti HIV2 antibodies) or a known history of HIV infection, active or in remission.
  • Positive result on any of the following tests: surface antigen (HBsAg), anti hepatitis B core antibodies (anti HBc Ab), anti virus antibodies (HCV-Ab).
  • If female, pregnant and/or breastfeeding.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    SAR441344

    SAR441344 single intravenous (IV) loading dose on Day 1 followed by a single subcutaneous (SC) dose administered once every 2 weeks from Week 2 to Week 10 (5 administrations)

    Drug: SAR441344

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • Pharmaceutical form: solution for injection Route of administration: intravenous or subcutaneous

  • DrugPlacebo

    Pharmaceutical form: solution for injection Route of administration: intravenous or subcutaneous

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in ESSDAI Score

    ESSDAI is validated and established outcome measurement for therapeutic efficacy in Sjögren's syndrome, evaluating disease activity mainly on extra-glandular manifestations. This score consists of 12 organ-specific domains (constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral and central nervous system, hematological, biological), which are scored based on organ-specific items in 3 to 4 different severity grades (no, low, moderate, high; with 0=no and 3=high). These scores are summed up over all 12 domains in weighted way (severity grades are multiplied with weights ranging 1-6 depending on domain) to summarize into total score(0-123). Higher scores indicates worse outcome. Negative change from baseline indicates improvement. Baseline=Day 1 assessment value. Least squares (LS) mean is calculated using mixed models for repeated measures (MMRM). Observed values after occurrence of intercurrent events are excluded.

    Time frame: Baseline (Day 1) to Week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI) Score

    The ESSPRI is a validated and established outcome measurement, reported by participants, which rates the key disease manifestations: fatigue, dryness, and pain, based on a numeric scale ranging from 0 to 10, where 0 is defined as no symptoms and 10 as maximum imaginable complaints. The total score is the mean score of the 3 scales and ranges from 0 to 10. Higher scores indicates worse outcome. A negative change from baseline indicates improvement. Baseline is defined as Day 1 assessment value. LS mean is calculated using MMRM. Observed values after occurrence of intercurrent events are excluded.

    Time frame: Baseline (Day 1) to Week 12

  2. Change From Baseline to Week 12 in Multidimensional Fatigue Inventory (MFI) General Fatigue Subscale and Other Subscales Score

    The MFI is a validated, 20 item self-report instrument to evaluate fatigue by investigating the following subscales: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Each subscale consists of 4 items that are scored using a scale from 1 ("yes, this is true") to 5 ("no, this is not true") on which the participants indicate how the listed statements applied to their current fatigue situation. Item scores are summed to create individual subscale score ranging from 4 to 20. A higher score indicates a higher degree of fatigue. A negative change from baseline indicates improvement. Baseline is defined as Day 1 assessment value. LS mean is calculated using ANCOVA. Observed values after occurrence of intercurrent events are excluded.

    Time frame: Baseline (Day 1) to Week 12

  3. Mean Plasma Concentration of SAR441344

    Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344.

    Time frame: At end of infusion and 4 hours post-infusion on Day 1; pre-dose at Weeks 2, 4, 6, 8, 10, and at Week 12

  4. Median Plasma Concentration of SAR441344

    Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344.

    Time frame: At end of infusion and 4 hours post-infusion on Day 1; pre-dose at Weeks 2, 4, 6, 8, 10, and at Week 12

  5. Maximum Plasma Concentration (Cmax) of SAR441344

    Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. Cmax was assessed by a Bayesian approach using the population PK model.

    Time frame: After the last SC dose on Week 10 up to 336 hours post-dose

  6. Time to Maximum Plasma Concentration (Tmax) of SAR441344

    Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. tmax was assessed by a Bayesian approach using the population PK model.

    Time frame: After the last SC dose on Week 10 up to 336 hours post-dose

  7. Area Under the Curve Over the Dosing Interval (AUC0-tau) of SAR441344

    Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. AUC0-tau was assessed by a Bayesian approach using the population PK model.

    Time frame: After the last SC dose on Week 10 up to 336 hours post-dose

  8. Terminal Half-life (t1/2z) of SAR441344

    Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. t1/2z was assessed by a Bayesian approach using the population PK model.

    Time frame: Week 10 to Week 12

  9. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Adverse Events of Special Interest (AESI)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. TEAEs: AEs that occurred, worsened, or became serious during the TEAE period (time from the first IMP administration up to Week 24). Serious adverse events (SAE): Any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or was a congenital anomaly/birth defect. An AESI: an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.

    Time frame: From first dose of IMP (Day 1) up to end of follow-up period (Week 24)

  10. Number of Participants With Treatment Discontinuation and Withdrawals Due to TEAEs

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. TEAEs were AEs that occurred, worsened, or became serious during the TEAE period (time from the first IMP administration up to Week 24).

    Time frame: From first dose of IMP (Day 1) up to end of follow-up period (Week 24)

  11. Number of Participants With Increase in Pain Intensity Compared to Pre-dose Pain Intensity at Injection Site by Verbal Descriptor Scale (VDS)

    For the measurement of local tolerability, participants had a self-evaluation using a VDS before IMP administration, after completion of the IMP administration, and 2 hours post-administration. The participants were asked to report sensations at the injection site and rated the pain severity as following grading: 0= no pain; 1= mild pain; 2= moderate pain, 3= severe pain, 4= very severe. A positive change in VDS score indicated a higher pain severity compared to the pre-dose pain. The numerical change provides the number of grades the pain got worse (positive change) or improved (negative change). Total number of participants with pain intensity increase (change in VDS score of greater than or equal to 1) compared to pre-dose pain intensity are reported.

    Time frame: Pre-dose (within 24 hours prior IMP dosing), post-dose (up to 15 minutes after dosing) and 2 hours post-dose at Weeks 2, 4, 6, 8 and 10

  12. Number of Participants With AEs Related to Local Tolerability Findings

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Local tolerability at injection site was assessed following IMP injection and findings at the site of injection such as injection site erythema, injection site reaction, and injection site pain were recorded.

    Time frame: Baseline (Day 1) to Week 10

  13. Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital Signs

    PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Sitting systolic blood pressure (SSBP) less than or equal to (≤)95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg; ≥160 mmHg and increase from baseline ≥20 mmHg; Sitting diastolic blood pressure (SDBP) ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥110 mmHg and increase from baseline ≥10 mmHg; Sitting heart rate (HR) ≤50 beats per minute (bpm) and decrease from baseline ≥20 bpm, ≥120 bpm and increase from baseline ≥20 bpm; Weight ≥5% decrease from baseline, ≥5% increase from baseline.

    Time frame: Baseline (Day 1) to Week 24

  14. Number of Participants With PCSA in Electrocardiogram

    PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: HR \<50 bpm, \<40 bpm, \>90 bpm, \>90 bpm and increase from baseline ≥20 bpm, \>100 bpm; PR interval, aggregate \>200 milliseconds (msec), \>200 msec and increase from baseline ≥25%, \>220 msec, \>220 msec and increase from baseline ≥25%, \>240 msec, \>240 msec and increase from baseline ≥25%; QRS duration, aggregate \>110 msec, \>110 msec and increase from baseline ≥25%, \>120 msec, \>120 msec and increase from baseline ≥25%; QT interval, aggregate \>500 msec; corrected QT (QTc) correction method unspecified \>450 msec, \>480 msec, increase from baseline \[30-60\] msec, increase from baseline \>60 msec.

    Time frame: Baseline (Day 1) to Week 24

  15. Number of Participants With PCSA in Hematology Parameters

    PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hemoglobin (Hb) ≤115 grams per liter (g/L) (Male \[M\]) or ≤95 g/L (Female \[F\]), ≥185 g/L (M) or ≥165 g/L (F), decrease from baseline ≥20 g/L; Hematocrit ≤0.37 volume per volume (v/v) (M) or ≤0.32 v/v (F), ≥0.55 v/v (M) or ≥0.5 v/v (F); Erythrocytes (red blood cells \[RBC\]) ≥6 x 10\^12 per liter (/L); Platelets \<100 x 10\^9/L, ≥700 x 10\^9/L; Leukocytes (white blood cells \[WBC\]) \<3 x 10\^9/L (Non-Black\[NB\]) or \<2 x 10\^9/L (Black\[B\]), ≥16 x 10\^9/L; Neutrophils \<1.5 x 10\^9/L (NB) or \<1 x 10\^9/L (B); Lymphocytes \>4 x 10\^9/L, \<0.5 x 10\^9L; Monocytes \>0.7 x 10\^9/L; Basophils \>0.1 x 10\^9/L; Eosinophils \>0.5 x 10\^9/L or \>upper limit of normal(ULN) (if ULN ≥0.5 x 10\^9/L).

    Time frame: Baseline (Day 1) to Week 24

  16. Number of Participants With PCSA in Clinical Chemistry Parameters

    PCSA values:abnormal values considered medically important by Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by Sponsor.Criteria for PCSA:Sodium≤129 millimoles per liter(mmol/L),≥160 mmol/L;Potassium\<3 mmol/L,≥5.5 mmol/L;Glucose≤3.9 mmol/L and \<lower limit of normal(LLN),≥11.1 mmol/L(unfasted);≥7 mmol/L(fasted); Creatine kinase(CK)\>3 ULN,\>10 ULN;Creatinine≥150 micromoles/L(adults),≥30% change from baseline,≥100% change from baseline;Creatinine clearance(CG)≥60-\<90 milliliters per minute(mL/min)(mild decrease in glomerular filtration rate\[GFR\]),≥30-\<60 mL/min(moderate decrease in GFR),≥15-\<30 mL/min(severe decrease in GFR),\<15 mL/min(end stage renal disease),Urea nitrogen≥17 mmol/L;Alkaline phosphatase(ALP)\>1.5 ULN;Alanine aminotransferase(ALT)\>3 ULN; ALT\>3 ULN and bilirubin\>2 ULN;Aspartate aminotransferase(AST)\>3 ULN;Direct bilirubin\>35% bilirubin and bilirubin\>1.5 ULN;Total bilirubin\>1.5 ULN,\>2 ULN.

    Time frame: Baseline (Day 1) to Week 24

  17. Number of Participants With PCSA in Urinalysis Parameters

    PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Potential of hydrogen (pH) ≤4.6 or ≥8.

    Time frame: Baseline (Day 1) to Week 24

  18. Number of Participants With Anti-drug Antibodies (ADA) to SAR441344

    Serum samples were collected at the specified timepoints for the assessment of ADAs to SAR441344. Number of participants with treatment-emergent ADA defined as at least 1 treatment-induced/boosted ADA during the treatment-emergent period, i.e. from the time of the IMP administration up to the end of study visit are reported. Number of participants with positive ADA are reported.

    Time frame: Baseline, Week 4, Week 8, Week 12, and Week 24

07

Results

Posted Oct 9, 2025

Participant flow

The study was conducted at 35 centers in 12 countries. A total of 234 participants were screened from 12 November 2020 to 10 August 2023, of which 150 were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.

Participant flow — Overall Study
MilestonePlaceboSAR441344
Started4242
Completed3940
Not completed32
Withdrew: Adverse event11
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryChange From Baseline to Week 12 in ESSDAI Score

ESSDAI is validated and established outcome measurement for therapeutic efficacy in Sjögren's syndrome, evaluating disease activity mainly on extra-glandular manifestations. This score consists of 12 organ-specific domains (constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral and central nervous system, hematological, biological), which are scored based on organ-specific items in 3 to 4 different severity grades (no, low, moderate, high; with 0=no and 3=high). These scores are summed up over all 12 domains in weighted way (severity grades are multiplied with weights ranging 1-6 depending on domain) to summarize into total score(0-123). Higher scores indicates worse outcome. Negative change from baseline indicates improvement. Baseline=Day 1 assessment value. Least squares (LS) mean is calculated using mixed models for repeated measures (MMRM). Observed values after occurrence of intercurrent events are excluded.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in ESSDAI Score
score on a scalePlaceboSAR441344
Change From Baseline to Week 12 in ESSDAI Score-5.60 ± 0.60-5.29 ± 0.59
Statistical analysis
  • Placebo vs SAR441344 · Least square mean difference: 0.32 · 95% CI -1.39 to 2.02
SecondaryChange From Baseline to Week 12 in European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI) Score

The ESSPRI is a validated and established outcome measurement, reported by participants, which rates the key disease manifestations: fatigue, dryness, and pain, based on a numeric scale ranging from 0 to 10, where 0 is defined as no symptoms and 10 as maximum imaginable complaints. The total score is the mean score of the 3 scales and ranges from 0 to 10. Higher scores indicates worse outcome. A negative change from baseline indicates improvement. Baseline is defined as Day 1 assessment value. LS mean is calculated using MMRM. Observed values after occurrence of intercurrent events are excluded.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI) Score
score on a scalePlaceboSAR441344
Change From Baseline to Week 12 in European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI) Score-2.21 ± 0.34-1.92 ± 0.34
SecondaryChange From Baseline to Week 12 in Multidimensional Fatigue Inventory (MFI) General Fatigue Subscale and Other Subscales Score

The MFI is a validated, 20 item self-report instrument to evaluate fatigue by investigating the following subscales: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Each subscale consists of 4 items that are scored using a scale from 1 ("yes, this is true") to 5 ("no, this is not true") on which the participants indicate how the listed statements applied to their current fatigue situation. Item scores are summed to create individual subscale score ranging from 4 to 20. A higher score indicates a higher degree of fatigue. A negative change from baseline indicates improvement. Baseline is defined as Day 1 assessment value. LS mean is calculated using ANCOVA. Observed values after occurrence of intercurrent events are excluded.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Multidimensional Fatigue Inventory (MFI) General Fatigue Subscale and Other Subscales Score
score on a scalePlaceboSAR441344
General Fatigue Scale Score0.37 ± 0.30-0.18 ± 0.30
Mental Fatigue Scale Score0.26 ± 0.360.37 ± 0.36
Physical Fatigue Scale Score0.27 ± 0.36-0.30 ± 0.36
Reduced Activity Scale Score0.22 ± 0.310.29 ± 0.31
Reduced Motivation Scale Score0.30 ± 0.300.26 ± 0.29
SecondaryMean Plasma Concentration of SAR441344

Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344.

Time frame:
At end of infusion and 4 hours post-infusion on Day 1; pre-dose at Weeks 2, 4, 6, 8, 10, and at Week 12
Reported as:
Mean · microgram per milliliter (mcg/mL)
Mean Plasma Concentration of SAR441344
microgram per milliliter (mcg/mL)SAR441344
Day 1 (end of infusion)466.10 ± 93.86
Day 1 (4 hours post-infusion)427.22 ± 102.07
Week 2 (pre-dose)139.98 ± 28.30
Week 4 (pre-dose)132.91 ± 36.21
Week 6 (pre-dose)135.18 ± 46.39
Week 8 (pre-dose)141.34 ± 44.85
Week 10 (pre-dose)142.25 ± 48.80
Week 12151.59 ± 56.49
SecondaryMedian Plasma Concentration of SAR441344

Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344.

Time frame:
At end of infusion and 4 hours post-infusion on Day 1; pre-dose at Weeks 2, 4, 6, 8, 10, and at Week 12
Reported as:
Median · mcg/mL
Median Plasma Concentration of SAR441344
mcg/mLSAR441344
Day 1 (end of infusion)479.06 (302.4 to 652.2)
Day 1 (4 hours post-infusion)408.37 (253.1 to 623.6)
Week 2 (pre-dose)132.21 (98.3 to 203.1)
Week 4 (pre-dose)133.01 (45.6 to 236.5)
Week 6 (pre-dose)127.32 (60.2 to 237.5)
Week 8 (pre-dose)135.10 (76.9 to 284.9)
Week 10 (pre-dose)134.39 (58.0 to 268.1)
Week 12148.11 (64.4 to 306.2)
SecondaryMaximum Plasma Concentration (Cmax) of SAR441344

Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. Cmax was assessed by a Bayesian approach using the population PK model.

Time frame:
After the last SC dose on Week 10 up to 336 hours post-dose
Reported as:
Mean · mcg/mL
Maximum Plasma Concentration (Cmax) of SAR441344
mcg/mLSAR441344
Maximum Plasma Concentration (Cmax) of SAR441344190 ± 54.5
SecondaryTime to Maximum Plasma Concentration (Tmax) of SAR441344

Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. tmax was assessed by a Bayesian approach using the population PK model.

Time frame:
After the last SC dose on Week 10 up to 336 hours post-dose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of SAR441344
hoursSAR441344
Time to Maximum Plasma Concentration (Tmax) of SAR44134489.1 (76.8 to 139)
SecondaryArea Under the Curve Over the Dosing Interval (AUC0-tau) of SAR441344

Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. AUC0-tau was assessed by a Bayesian approach using the population PK model.

Time frame:
After the last SC dose on Week 10 up to 336 hours post-dose
Reported as:
Mean · microgram*hour per milliliter (mcg*h/mL)
Area Under the Curve Over the Dosing Interval (AUC0-tau) of SAR441344
microgram*hour per milliliter (mcg*h/mL)SAR441344
Area Under the Curve Over the Dosing Interval (AUC0-tau) of SAR44134457900 ± 18000
SecondaryTerminal Half-life (t1/2z) of SAR441344

Blood samples were collected at the specified timepoints for the measurement of plasma concentrations of SAR441344. t1/2z was assessed by a Bayesian approach using the population PK model.

Time frame:
Week 10 to Week 12
Reported as:
Median · hours
Terminal Half-life (t1/2z) of SAR441344
hoursSAR441344
Terminal Half-life (t1/2z) of SAR441344662 (374 to 997)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Adverse Events of Special Interest (AESI)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. TEAEs: AEs that occurred, worsened, or became serious during the TEAE period (time from the first IMP administration up to Week 24). Serious adverse events (SAE): Any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or was a congenital anomaly/birth defect. An AESI: an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.

Time frame:
From first dose of IMP (Day 1) up to end of follow-up period (Week 24)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Adverse Events of Special Interest (AESI)
ParticipantsPlaceboSAR441344
Any TEAE2629
Any TESAE11
Any AESI54
SecondaryNumber of Participants With Treatment Discontinuation and Withdrawals Due to TEAEs

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. TEAEs were AEs that occurred, worsened, or became serious during the TEAE period (time from the first IMP administration up to Week 24).

Time frame:
From first dose of IMP (Day 1) up to end of follow-up period (Week 24)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Discontinuation and Withdrawals Due to TEAEs
ParticipantsPlaceboSAR441344
Treatment discontinuation due to TEAEs44
Treatment withdrawal due to TEAEs00
SecondaryNumber of Participants With Increase in Pain Intensity Compared to Pre-dose Pain Intensity at Injection Site by Verbal Descriptor Scale (VDS)

For the measurement of local tolerability, participants had a self-evaluation using a VDS before IMP administration, after completion of the IMP administration, and 2 hours post-administration. The participants were asked to report sensations at the injection site and rated the pain severity as following grading: 0= no pain; 1= mild pain; 2= moderate pain, 3= severe pain, 4= very severe. A positive change in VDS score indicated a higher pain severity compared to the pre-dose pain. The numerical change provides the number of grades the pain got worse (positive change) or improved (negative change). Total number of participants with pain intensity increase (change in VDS score of greater than or equal to 1) compared to pre-dose pain intensity are reported.

Time frame:
Pre-dose (within 24 hours prior IMP dosing), post-dose (up to 15 minutes after dosing) and 2 hours post-dose at Weeks 2, 4, 6, 8 and 10
Reported as:
Count of participants · Participants
Number of Participants With Increase in Pain Intensity Compared to Pre-dose Pain Intensity at Injection Site by Verbal Descriptor Scale (VDS)
ParticipantsPlaceboSAR441344
Week 2: Post-dose versus pre-dose77
Week 2: 2 hours post-dose versus pre-dose58
Week 4: Post-dose versus pre-dose128
Week 4: 2 hours post-dose versus pre-dose56
Week 6: Post-dose versus pre-dose1310
Week 6: 2 hours post-dose versus pre-dose33
Week 8: Post-dose versus pre-dose711
Week 8: 2 hours post-dose versus pre-dose31
Week 10: Post-dose versus pre-dose710
Week 10: 2 hours post-dose versus pre-dose51
SecondaryNumber of Participants With AEs Related to Local Tolerability Findings

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Local tolerability at injection site was assessed following IMP injection and findings at the site of injection such as injection site erythema, injection site reaction, and injection site pain were recorded.

Time frame:
Baseline (Day 1) to Week 10
Reported as:
Count of participants · Participants
Number of Participants With AEs Related to Local Tolerability Findings
ParticipantsPlaceboSAR441344
Injection site erythema13
Injection site reaction20
Injection site pain10
SecondaryNumber of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital Signs

PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Sitting systolic blood pressure (SSBP) less than or equal to (≤)95 millimeters of mercury (mmHg) and decrease from baseline ≥20 mmHg; ≥160 mmHg and increase from baseline ≥20 mmHg; Sitting diastolic blood pressure (SDBP) ≤45 mmHg and decrease from baseline ≥10 mmHg, ≥110 mmHg and increase from baseline ≥10 mmHg; Sitting heart rate (HR) ≤50 beats per minute (bpm) and decrease from baseline ≥20 bpm, ≥120 bpm and increase from baseline ≥20 bpm; Weight ≥5% decrease from baseline, ≥5% increase from baseline.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital Signs
ParticipantsPlaceboSAR441344
SSBP: ≤95 mmHg; decrease from baseline ≥20 mmHg22
SSBP: ≥160 mmHg; increase from baseline ≥20 mmHg00
SDBP: ≤45 mmHg; decrease from baseline ≥10 mmHg00
SDBP: ≥110 mmHg; increase from baseline ≥10 mmHg00
Sitting HR: ≤50 bpm; decrease from baseline ≥20 bpm10
Sitting HR: ≥120 bpm; increase from baseline ≥20 bpm00
Weight: ≥5% decrease from baseline63
Weight: ≥5% increase from baseline23
SecondaryNumber of Participants With PCSA in Electrocardiogram

PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: HR \<50 bpm, \<40 bpm, \>90 bpm, \>90 bpm and increase from baseline ≥20 bpm, \>100 bpm; PR interval, aggregate \>200 milliseconds (msec), \>200 msec and increase from baseline ≥25%, \>220 msec, \>220 msec and increase from baseline ≥25%, \>240 msec, \>240 msec and increase from baseline ≥25%; QRS duration, aggregate \>110 msec, \>110 msec and increase from baseline ≥25%, \>120 msec, \>120 msec and increase from baseline ≥25%; QT interval, aggregate \>500 msec; corrected QT (QTc) correction method unspecified \>450 msec, \>480 msec, increase from baseline \[30-60\] msec, increase from baseline \>60 msec.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Count of participants · Participants
Number of Participants With PCSA in Electrocardiogram
ParticipantsPlaceboSAR441344
HR: <50 bpm21
HR: <40 bpm00
HR: >90 bpm31
HR: >90 bpm; increase from baseline ≥20 bpm10
HR: >100 bpm00
PR interval, aggregate: >200 msec42
PR interval, aggregate: >200 msec; increase from baseline ≥25%10
PR interval, aggregate: >220 msec10
PR interval, aggregate: >220 msec; increase from baseline ≥25%00
PR interval, aggregate: >240 msec10
PR interval, aggregate: >240 msec; increase from baseline ≥25%00
QRS duration, aggregate: >110 msec20
QRS duration, aggregate: >110 msec; increase from baseline ≥25%00
QRS duration, aggregate: >120 msec10
QRS duration, aggregate: >120 msec; increase from baseline ≥25%00
QT interval, aggregate: >500 msec00
QTc correction method unspecified: >450 msec52
QTc correction method unspecified: >480 msec00
QTc correction method unspecified: Increase from baseline[30-60] msec37
QTc correction method unspecified: Increase from baseline >60 msec00
SecondaryNumber of Participants With PCSA in Hematology Parameters

PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Hemoglobin (Hb) ≤115 grams per liter (g/L) (Male \[M\]) or ≤95 g/L (Female \[F\]), ≥185 g/L (M) or ≥165 g/L (F), decrease from baseline ≥20 g/L; Hematocrit ≤0.37 volume per volume (v/v) (M) or ≤0.32 v/v (F), ≥0.55 v/v (M) or ≥0.5 v/v (F); Erythrocytes (red blood cells \[RBC\]) ≥6 x 10\^12 per liter (/L); Platelets \<100 x 10\^9/L, ≥700 x 10\^9/L; Leukocytes (white blood cells \[WBC\]) \<3 x 10\^9/L (Non-Black\[NB\]) or \<2 x 10\^9/L (Black\[B\]), ≥16 x 10\^9/L; Neutrophils \<1.5 x 10\^9/L (NB) or \<1 x 10\^9/L (B); Lymphocytes \>4 x 10\^9/L, \<0.5 x 10\^9L; Monocytes \>0.7 x 10\^9/L; Basophils \>0.1 x 10\^9/L; Eosinophils \>0.5 x 10\^9/L or \>upper limit of normal(ULN) (if ULN ≥0.5 x 10\^9/L).

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Count of participants · Participants
Number of Participants With PCSA in Hematology Parameters
ParticipantsPlaceboSAR441344
Hb: ≤115 g/L (M); ≤95 g/L (F)01
Hb: ≥185 g/L (M); ≥165 g/L (F)01
Hb: Decrease from baseline ≥20 g/L22
Hematocrit: ≤0.37 v/v (M); ≤0.32 v/v (F)53
Hematocrit: ≥0.55 v/v (M); ≥0.5 v/v (F)01
RBC: ≥6 x 10^12/L01
Platelets: <100 x 10^9/L00
Platelets: ≥700 x 10^9/L00
WBC: <3 x 10^9/L (NB); <2 x 10^9/L (B)85
WBC: ≥16 x 10^9/L00
Neutrophils: <1.5 x 10^9/L (NB); <1 x 10^9/L (B)77
Lymphocytes: >4 x 10^9/L01
Lymphocytes: <0.5 x 10^9L20
Monocytes: >0.7 x 10^9/L12
Basophils: >0.1 x 10^9/L08
Eosinophils: >0.5 x 10^9/L or >ULN10
SecondaryNumber of Participants With PCSA in Clinical Chemistry Parameters

PCSA values:abnormal values considered medically important by Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by Sponsor.Criteria for PCSA:Sodium≤129 millimoles per liter(mmol/L),≥160 mmol/L;Potassium\<3 mmol/L,≥5.5 mmol/L;Glucose≤3.9 mmol/L and \<lower limit of normal(LLN),≥11.1 mmol/L(unfasted);≥7 mmol/L(fasted); Creatine kinase(CK)\>3 ULN,\>10 ULN;Creatinine≥150 micromoles/L(adults),≥30% change from baseline,≥100% change from baseline;Creatinine clearance(CG)≥60-\<90 milliliters per minute(mL/min)(mild decrease in glomerular filtration rate\[GFR\]),≥30-\<60 mL/min(moderate decrease in GFR),≥15-\<30 mL/min(severe decrease in GFR),\<15 mL/min(end stage renal disease),Urea nitrogen≥17 mmol/L;Alkaline phosphatase(ALP)\>1.5 ULN;Alanine aminotransferase(ALT)\>3 ULN; ALT\>3 ULN and bilirubin\>2 ULN;Aspartate aminotransferase(AST)\>3 ULN;Direct bilirubin\>35% bilirubin and bilirubin\>1.5 ULN;Total bilirubin\>1.5 ULN,\>2 ULN.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Count of participants · Participants
Number of Participants With PCSA in Clinical Chemistry Parameters
ParticipantsPlaceboSAR441344
Sodium: ≤129 mmol/L00
Sodium: ≥160 mmol/L00
Potassium: <3 mmol/L00
Potassium: ≥5.5 mmol/L10
Glucose: ≤3.9 mmol/L and <LLN35
Glucose: ≥11.1 mmol/L (unfasted); ≥7 mmol/L (fasted)31
CK: >3 ULN01
CK: >10 ULN00
Creatinine: ≥150 micromoles/L (Adults)00
Creatinine: ≥30% change from baseline12
Creatinine: ≥100% change from baseline00
CG: ≥60 - <90 mL/min2416
CG: ≥30 - <60 mL/min32
CG: ≥15 - <30 mL/min00
CG: <15 mL/min00
Urea Nitrogen: ≥17 mmol/L00
ALP: >1.5 ULN01
ALT: >3 ULN00
ALT >3 ULN; Bilirubin >2 ULN00
AST: >3 ULN00
Direct Bilirubin >35% Bilirubin; Bilirubin >1.5 ULN00
Total Bilirubin: >1.5 ULN01
Total Bilirubin: >2 ULN00
SecondaryNumber of Participants With PCSA in Urinalysis Parameters

PCSA values were defined as abnormal values considered medically important by the Sponsor, according to predefined criteria/thresholds based on literature reviews and defined by the Sponsor. Criteria for PCSA: Potential of hydrogen (pH) ≤4.6 or ≥8.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Count of participants · Participants
Number of Participants With PCSA in Urinalysis Parameters
ParticipantsPlaceboSAR441344
pH ≤4.600
pH ≥832
SecondaryNumber of Participants With Anti-drug Antibodies (ADA) to SAR441344

Serum samples were collected at the specified timepoints for the assessment of ADAs to SAR441344. Number of participants with treatment-emergent ADA defined as at least 1 treatment-induced/boosted ADA during the treatment-emergent period, i.e. from the time of the IMP administration up to the end of study visit are reported. Number of participants with positive ADA are reported.

Time frame:
Baseline, Week 4, Week 8, Week 12, and Week 24
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA) to SAR441344
ParticipantsSAR441344
Baseline2
Week 42
Week 82
Week 120
Week 245

Adverse events

Collected over From first dose of IMP (Day 1) up to end of follow-up period (Week 24). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/42 (0%)1/42 (2.4%)20/42 (47.6%)
SAR4413440/42 (0%)1/42 (2.4%)15/42 (35.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboSAR441344
Osteomyelitis AcuteInfections and infestations1/420/42
Device BreakageProduct Issues0/421/42
Most frequent other events
Most frequent other events
EventPlaceboSAR441344
Urinary Tract InfectionInfections and infestations6/421/42
Accidental OverdoseInjury, poisoning and procedural complications5/424/42
Covid-19Infections and infestations4/424/42
NeutropeniaBlood and lymphatic system disorders2/424/42
NasopharyngitisInfections and infestations3/421/42
HeadacheNervous system disorders0/423/42
Abdominal PainGastrointestinal disorders3/420/42
DiarrhoeaGastrointestinal disorders3/420/42
ArthralgiaMusculoskeletal and connective tissue disorders3/420/42
Injection Site ErythemaGeneral disorders1/423/42

Baseline characteristics

Safety population included all randomized participants exposed to the investigational medicinal product (IMP) (regardless of the amount of treatment administered).

Age, Continuous
Age, Continuous(years)PlaceboSAR441344Total
Mean47.8 ± 12.949.2 ± 11.148.5 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSAR441344Total
Female404080
Male224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSAR441344Total
White342862
Black or African American145
Asian549
American Indian or Alaska Native167
Missing/Not reported101
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score(score on a scale)PlaceboSAR441344Total
Mean10.38 ± 3.648.43 ± 3.889.40 ± 3.87
08

Study locations

36 sites
  • Omega Research Consultants Debary Site Number : 8400005
    DeBary, Florida 32713, United States
  • Altoona Center For Clinical Research Site Number : 8400001
    Duncansville, Pennsylvania 16635, United States
  • Ramesh C. Gupta, M.D. Site Number : 8400007
    Memphis, Tennessee 38119, United States
  • Prolato Clinical Research Center Site Number : 8400009
    Houston, Texas 77054, United States
  • Investigational Site Number : 0320004
    CABA, Buenos Aires 1430, Argentina
  • Investigational Site Number : 0320002
    CABA, Buenos Aires C1111, Argentina
  • Investigational Site Number : 0320003
    Pergamino, Buenos Aires B2700CPM, Argentina
  • Investigational Site Number : 0320001
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
  • Investigational Site Number : 0560002
    Ghent, 9000, Belgium
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Investigational Site Number : 1240001
    Sherbrooke, Quebec J1L 0H8, Canada
  • Investigational Site Number : 1520002
    Osorno, Los Lagos Region 5311092, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 7640881, Chile
  • Investigational Site Number : 1520004
    Viña del Mar, Valparaiso 2520598, Chile
  • Investigational Site Number : 2500003
    Limoges, 87042, France
  • Investigational Site Number : 2500005
    Marseille, 13003, France
  • Investigational Site Number : 2500001
    Montpellier, 34295, France
  • Investigational Site Number : 2500004
    Paris, 75010, France
  • Investigational Site Number : 2500006
    Paris, 75013, France
  • Investigational Site Number : 2500002
    Strasbourg, 67098, France
  • Investigational Site Number : 2760001
    Berlin, 10117, Germany
  • Investigational Site Number : 3480003
    Budapest, 1036, Hungary
  • Investigational Site Number : 3480001
    Debrecen, 4032, Hungary
  • Investigational Site Number : 3480004
    Székesfehérvár, 8000, Hungary
  • Investigational Site Number : 4840002
    Mexicali, Estado de Baja California 21200, Mexico
  • Investigational Site Number : 4840001
    Monterrey, Nuevo León 64460, Mexico
  • Investigational Site Number : 4840003
    Chihuahua City, 31020, Mexico
  • Investigational Site Number : 4100004
    Daegu, Daegu 561-712, South Korea
  • Investigational Site Number : 4100002
    Seoul, Seoul-teukbyeolsi 03080, South Korea
  • Investigational Site Number : 4100001
    Seoul, 06591, South Korea
  • Investigational Site Number : 7240003
    Seville, Andalusia 41010, Spain
  • Investigational Site Number : 7240002
    Málaga, 29010, Spain
  • Investigational Site Number : 1580002
    Taichung, 40447, Taiwan
  • Investigational Site Number : 1580003
    Tainan, 704, Taiwan
  • Investigational Site Number : 1580001
    Taipei, 100, Taiwan
  • Investigational Site Number : 1580005
    Taoyuan County, 33305, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Nov 2023, 35 months.

Results were first posted in Oct 2025, 1 year 11 months after primary completion. A results delay was requested in Nov 2024.

Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2020
First posted
Oct 1, 2020
StartActual
Nov 12, 2020
Primary completionActual
Nov 8, 2023
CompletionActual
Feb 9, 2024
Results delay requested
Nov 6, 2024
Results first posted
Oct 9, 2025
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04572841
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 1, 2020
Start date
Nov 12, 2020
Primary completion
Nov 8, 2023
Completion
Feb 9, 2024
Results posted
Oct 9, 2025
Last update
Oct 9, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Frexalimab

Start the discussion